Welcome to our dedicated page for SCYNEXIS SEC filings (Ticker: SCYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SCYNEXIS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SCYNEXIS's regulatory disclosures and financial reporting.
SCYNEXIS (SCYX) reported an insider transaction on a Form 4. On 10/17/2025, a company Chief Executive Officer and Director acquired 32,500 shares of common stock at $0.76 per share. Following this trade, the insider’s beneficial ownership stands at 853,098 shares, held directly.
The filing notes this total includes 4,000 shares acquired under the 2014 Employee Stock Purchase Plan on 09/05/2025.
SCYNEXIS (SCYX) entered a binding memorandum of understanding with GSK to amend their exclusive license, resolving the prior disagreement over the Phase 3 MARIO study of ibrexafungerp. SCYNEXIS will promptly wind down and terminate the MARIO study and will receive $22 million from GSK, plus an additional $2.3 million in connection with the wind-down and termination activities. SCYNEXIS will not receive additional milestone payments specifically tied to MARIO.
GSK reiterated its commitment to the broader collaboration, including commercialization of BREXAFEMME (ibrexafungerp tablets) for VVC and rVVC. SCYNEXIS continues to progress the transfer of the BREXAFEMME NDA to GSK by the end of 2025. GSK anticipates initiating FDA interactions in 2026 to discuss a U.S. relaunch for VVC and rVVC. Other potential milestones and royalties under the exclusive license remain unchanged.
Federated Hermes, Inc. and related Reporting Persons report beneficial ownership of 5,116,598 shares of Scynexis Inc. common stock, representing 11.26% of the outstanding shares as of the event date 09/30/2025. The filing is an Amendment to Schedule 13G and lists ownership held by Federated Hermes, Inc., Voting Shares Irrevocable Trust, and three individual reporting persons who share voting and dispositive power over the same block. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures for the filing and trust acknowledgments are dated 10/07/2025, with exhibits noted for subsidiary classification, a joint filing agreement, and a power of attorney.
SCYNEXIS, Inc. reported that the FDA lifted the clinical hold on ibrexafungerp on April 24, 2025, and dosing in the Phase 3 MARIO study resumed in May 2025, prompting the company to bill a $10.0 million development milestone to GSK in Q2 2025. The company is disputing GSK’s April 28, 2025 notice that purported to terminate the MARIO study and deny further milestone payments, including a $30.0 million milestone tied to study resumption.
Financially, SCYNEXIS recognized $1.364 million in license revenue for the quarter and reported a net loss of $6.885 million for Q2 2025 ($12.276 million year-to-date). Cash and investments totaled $46.5 million at June 30, 2025 (down from $75.1 million at year-end), the March 2019 convertible notes were repaid $14.0 million in March 2025, and the accumulated deficit was $388.8 million. The company received a Nasdaq deficiency notice on June 20, 2025 for a closing bid below $1.00 and has until December 17, 2025 to regain compliance. Ongoing securities class and derivative lawsuits remain pending.